Home
This site is intended for healthcare professionals
Sign upLog in

Personalized Pathways: Confidence and Coordination in Biomarker-Guided Muscle-Invasive Bladder Cancer Care

After participating you can claim your CME credit here

Accreditation: 0.25 AMA PRA Category 1 Credit™

Learning objectives

Upon completion of this activity, participants should be better able to:

  1. Critically appraise clinical trial designs and methodologies to differentiate between prospective, treatment-guiding use of ctDNA and retrospective, prognostic analyses, accurately interpreting the evidentiary strength, limitations, and clinical applicability of each within contemporary adjuvant decision-making frameworks.
  2. Apply practical, evidence-based models for cross-specialty coordination among urologists, oncologists, and advanced practice providers to ensure timely initiation of tumor-informed MRD testing, appropriate sample handling, and integration of serial ctDNA monitoring into perioperative care pathways.
  3. Interpret ctDNA results to inform patient-centered treatment decisions, balancing escalation (adjuvant therapy initiation) and de-escalation (active surveillance) strategies, and demonstrating confidence managing molecular recurrence (ctDNA conversion) or persistently negative findings in alignment with current evidence and multidisciplinary consensus.

This program is supported by an independent educational grant from Genentech. This accredited education activity is available to U.S. healthcare professionals only.

Who Should Attend?

This program is designed for U.S.-based healthcare professionals involved in the management of patients with muscle-invasive bladder cancer, including: Community medical oncologists, Urologists, Oncology nurse practitioners, Physician assistants, Other healthcare professionals interested in muscle-invasive bladder cancer.

Faculty

Matthew Galsky, MD

Dr. Galsky is a medical oncologist specializing in genitourinary malignancies, with a primary focus on bladder cancer. His clinical and research interests include biomarker-driven treatment strategies, perioperative and adjuvant therapy decision-making, and the integration of circulating tumor DNA into clinical practice. He has extensive experience translating emerging clinical trial data into practical, multidisciplinary approaches to patient-centered bladder cancer care.

John P. Sfakianos, MD

Dr. Sfakianos is a urologic oncologist specializing in the surgical management of bladder cancer and perioperative care coordination. His clinical expertise includes radical cystectomy, post-surgical risk assessment, and multidisciplinary collaboration to guide adjuvant treatment and surveillance strategies. He has a strong interest in integrating molecular diagnostics, including tumor-informed ctDNA testing, to support individualized decision-making following surgery.

Continuing Education Information

This continuing education activity will be provided by Current Concepts Institute (CCI) and MedAll. Physicians, Nurse Practitioners, and Physician Assistants will be eligible for AMA PRA Category 1 Credit™. A statement of participation is available for other healthcare professionals.

Unapproved and/or off-label use disclosure
Current Concepts Institute/MedAll requires CE faculty to disclose to the participants:

  1. When products or procedures being discussed are off-label, unlabelled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and

  2. Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Disclosures
Below is a listing of all individuals who are involved in the planning and implementation of this accredited continuing education activity. All relevant financial relationships listed for these individuals have been mitigated.

Matthew Galsky, MD has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Consultant for Merck, Research Support from Merck, Travel from Pfizer. These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education. Dr. Galsky may reference any unlabeled or unapproved uses of products during the presentation. He will disclose to the audience when this discussion takes place.

John P. Sfakianos, MD has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Advisory Board for CG oncology, Johnson & Johnson, Natera, Urogen, Speakers Bureau participant with Natera, Immunity Bio, Urogen. These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education. Dr. Galsky may reference any unlabeled or unapproved uses of products during the presentation. He will disclose to the audience when this discussion takes place.

CCI staff (Christine Heim), MedAll staff (Gabriele Marija Baltrusyte, Phil McElnay, Judith Lewis, and Gemma Thomas) have no relevant financial relationships with ineligible companies to disclose.

Activity Accreditation for Health Professions

Physicians

0.25 AMA PRA Category 1 Credits™ are available for this activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Current Concepts Institute and MedAll Education. Current Concepts Institute is accredited by the ACCME to provide continuing medical education for physicians.

Current Concepts Institute designates this online activity a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

Participation Costs

There is no cost to participate in this program.

This continuing education activity is active starting March 2026 and will expire on 1 March 2027.

Estimated time to complete this activity: 15 min